<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------
SCHEDULE 13D
(RULE 13D-101)
UNDER THE SECURITIES EXCHANGE ACT OF 1934/1/
MICROCIDE PHARMACEUTICALS, INC.
-------------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
59501 8 102
-----------
(CUSIP Number)
Hope Flack
BVF Partners L.P.
333 West Wacker Drive, Suite 1600
Chicago, Illinois 60606
(312) 263-7777
--------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
August 7, 1997
--------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom
copies are to be sent.
(Continued on following pages)
(Page 1 of 8 Pages)
- -----------------------------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 2 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BIOTECHNOLOGY VALUE FUND, L.P.
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [X] (b) [_]
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_]
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OR ORGANIZATION
DELAWARE
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF -0-
SHARES -----------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 303,200
REPORTING -----------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH -0-
-----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
303,200
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
303,200
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES*
[_]
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
2.8%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 3 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BVF PARTNERS L.P.
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [X] (b) [_]
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
00
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_]
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OR ORGANIZATION
DELAWARE
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF -0-
SHARES -----------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 552,800
REPORTING -----------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH -0-
-----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
552,800
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
552,800
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES*
[_]
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.1%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 4 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BVF INC.
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [X] (b) [_]
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC,OO
- ------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_]
- ------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OR ORGANIZATION
DELAWARE
- ------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF -0-
SHARES -----------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 552,800
REPORTING -----------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH -0-
-----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
552,800
- ------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
552,800
- ------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES*
[_]
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.1%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IA,CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 5 OF 8 PAGES
- ----------------------- ---------------------
ITEM 1. SECURITY AND ISSUER.
This Statement on Schedule 13D (this "Statement") relates to the Common
Stock, par value $.001 per share (the "Stock"), of Microcide Pharmaceuticals,
Inc., a Delaware corporation ("Microcide"). The principal executive office of
Microcide is located at 850 Maude Avenue, Mountain View, California 94043.
ITEM 2. IDENTITY AND BACKGROUND.
The persons filing this Statement, the persons enumerated in Instruction C
of Schedule 13D and, where applicable, their respective places of organization,
general partners, directors, executive officers and controlling persons, and
certain information regarding each of them, are as follows:
(a) Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"),
BVF Partners L.P., a Delaware limited partnership ("Partners"), BVF Inc., a
Delaware corporation ("BVF Inc."), and Mark N. Lampert, an individual
("Lampert") (collectively, the "Reporting Persons").
(b) The business address of BVF and Partners is 333 West Wacker Drive,
Suite 1600, Chicago, Illinois 60606. The business address of BVF Inc. and
Lampert is One Sansome Street, 39th Floor, San Francisco, California 94104.
(c) Partners is the general partner of BVF, which is an investment limited
partnership. BVF Inc. is an investment adviser to and general partner of
Partners. Lampert is the sole shareholder, sole director and an officer of BVF
Inc.
(d) During the last five years, none of such persons has been convicted in
a criminal proceeding (excluding traffic violations and similar misdemeanors).
(e) During the last five years, none of such persons was a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction and as
a result of such proceeding was or is subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violation with
respect to such laws.
(f) Lampert is a citizen of the United States of America.
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 6 OF 8 PAGES
- ----------------------- ---------------------
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Since June 13, 1997, Partners, in its capacity as general partner of BVF,
has purchased on behalf of such limited partnership an aggregate number of
168,500 shares of the Stock for an aggregate consideration of $1,899,921.50,
utilizing funds provided by BVF from its working capital pursuant to the terms
of its limited partnership agreement with Partners. In addition, Partners, in
its capacity as investment manager with respect to certain managed accounts, has
purchased on behalf of such managed accounts an aggregate number of 152,000
shares of the Stock for an aggregate consideration of $1,701,165.00, utilizing
funds under management by Partners pursuant to investment manager agreements
between Partners and such managed accounts.
ITEM 4. PURPOSE OF TRANSACTIONS.
The sole purpose of the acquisitions of the Stock reported herein is and
was for investment. The Reporting Persons did not at the time of such
acquisitions of the Stock, and do not presently, have any plan to acquire
control of Microcide. The Reporting Persons may acquire or dispose of
additional shares of the Stock from time to time.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) BVF beneficially owns 303,200 shares of the Stock, Partners
beneficially owns 552,800 shares of the Stock, and BVF Inc. beneficially owns
552,800 shares of the Stock, approximately 2.8%, 5.1% and 5.1%, respectively, of
the aggregate number of shares outstanding as of August 7, 1997.
(b) BVF shares voting and dispositive power over the 303,200 shares of the
Stock it beneficially owns with Partners. Partners and BVF Inc. share voting
and dispositive power over the 552,800 shares of the Stock they beneficially own
with, in addition to BVF, the managed accounts on whose behalf Partners, as
investment manager, purchased such shares. The managed accounts on whose behalf
Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited
liability company ("ILL10"), Palamundo, L.D.C., a limited duration company
organized under the laws of the Cayman Islands ("Palamundo"), ZPG Securities,
L.L.C., a New York limited liability company ("ZPG") and Biotechnology Value
Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd."). ILL10, Palamundo, ZPG
and BVF Ltd. are collectively referred to herein as the "Accounts." The
Accounts specialize in holding biotechnology stocks for investment purposes and
the business address of each is BVF Partners L.P., 333 West Wacker Drive,
Suite 1600, Chicago, Illinois 60606.
(c) Exhibit B attached hereto contains information as to all transactions
in the Stock by the Reporting Persons during the past 60 days. All such
transactions were made for
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 7 OF 8 PAGES
- ----------------------- ---------------------
cash in open market, over-the-counter transactions. No other transactions in the
Stock have been effected by the Reporting Persons during the past 60 days.
(d) The Accounts are entitled to receive dividends and any sale proceeds
with respect to the Stock in proportion to their respective ownership interests
therein.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Partners is the general partner of BVF pursuant to a limited partnership
agreement which authorizes Partners, among other things, to invest the funds of
BVF in the Stock and to vote and dispose of the Stock. Pursuant to such limited
partnership agreement, Partners is entitled to allocations based on assets under
management and realized and unrealized gains thereon. Pursuant to investment
management agreements with the Accounts, Partners and BVF Inc. have the
authority, among other things, to invest funds of the Accounts in the Stock and
to vote and dispose of the Stock. Pursuant to such agreements, Partners and BVF
Inc. receive fees based on assets under management and realized and unrealized
gains thereon. BVF Inc. is the general partner of Partners and may be deemed to
own beneficially securities over which Partners exercises voting and dispositive
power.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Exhibit A - Agreement Regarding Joint Filing
Exhibit B - Transactions in the Stock by the Reporting Persons during the
past 60 days.
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 8 OF 8 PAGES
- ----------------------- ---------------------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: August 29, 1997
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
----------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
---------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ Mark N. Lampert
--------------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
--------------------------------
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the statement
containing the information required by Schedule 13D, to which this Agreement is
attached as an exhibit, is filed on behalf of each of them. The undersigned
further agree that any amendments or supplements thereto shall also be filed on
behalf of each of them.
Dated: August 29, 1997
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
----------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
---------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ Mark N. Lampert
---------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT B
TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS
---------------------------------------------------
DURING THE PAST 60 DAYS
-----------------------
<TABLE>
<CAPTION>
Price
Settlement For the per
Date By Account of Quantity Share Type of Trade Broker
- ---------- ----------- ----------- -------- --------- ------------- ------
======================================================================================
<S> <C> <C> <C> <C> <C> <C>
06/13/97 Partners BVF 40,000 $11.4545 Purchase MLCO
- --------------------------------------------------------------------------------------
06/13/97 Partners BVF Ltd. 15,000 $11.4545 Purchase MLCO
- --------------------------------------------------------------------------------------
06/17/97 Partners BVF 6,000 $11.3750 Purchase ABSB
- --------------------------------------------------------------------------------------
06/17/97 Partners ILL10 3,000 $11.3750 Purchase ABSB
- --------------------------------------------------------------------------------------
06/17/97 Partners BVF Ltd. 3,000 $11.3750 Purchase ABSB
- --------------------------------------------------------------------------------------
06/25/97 Partners BVF 10,000 $11.3750 Purchase ABSB
- --------------------------------------------------------------------------------------
06/25/97 Partners ILL10 1,600 $11.5000 Purchase COWN
- --------------------------------------------------------------------------------------
06/25/97 Partners PAL 1,400 $11.5000 Purchase COWN
- --------------------------------------------------------------------------------------
06/25/97 Partners ZPG 1,200 $11.5000 Purchase COWN
- --------------------------------------------------------------------------------------
06/25/97 Partners BVF Ltd. 3,800 $11.5000 Purchase COWN
- --------------------------------------------------------------------------------------
06/25/97 Partners BVF 2,000 $11.5000 Purchase COWN
- --------------------------------------------------------------------------------------
06/26/97 Partners BVF 1,000 $11.3125 Purchase ABSB
- --------------------------------------------------------------------------------------
06/27/97 Partners PAL 10,000 $11.2500 Purchase COWN
- --------------------------------------------------------------------------------------
06/27/97 Partners ZPG 10,000 $11.1250 Purchase MLCO
- --------------------------------------------------------------------------------------
06/27/97 Partners BVF Ltd. 7,000 $11.1250 Purchase MLCO
- --------------------------------------------------------------------------------------
06/30/97 Partners BVF 46,500 $11.2310 Purchase COWN
- --------------------------------------------------------------------------------------
06/30/97 Partners ILL10 5,000 $11.2310 Purchase COWN
- --------------------------------------------------------------------------------------
06/30/97 Partners PAL 5,000 $11.2310 Purchase COWN
- --------------------------------------------------------------------------------------
06/30/97 Partners ZPG 2,500 $11.2310 Purchase COWN
- --------------------------------------------------------------------------------------
06/30/97 Partners BVF Ltd. 20,000 $11.2310 Purchase COWN
- --------------------------------------------------------------------------------------
07/02/97 Partners BVF 10,000 $10.6250 Purchase MLCO
- --------------------------------------------------------------------------------------
07/02/97 Partners ILL10 5,000 $10.6250 Purchase MLCO
- --------------------------------------------------------------------------------------
07/02/97 Partners PAL 5,000 $10.6250 Purchase MLCO
- --------------------------------------------------------------------------------------
07/02/97 Partners ZPG 2,500 $10.6250 Purchase MLCO
- --------------------------------------------------------------------------------------
07/02/97 Partners BVF Ltd. 7,500 $10.6250 Purchase MLCO
- --------------------------------------------------------------------------------------
07/25/97 Partners BVF 11,000 $11.5625 Purchase ABSB
- --------------------------------------------------------------------------------------
07/25/97 Partners ILL10 1,700 $11.5625 Purchase ABSB
- --------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Price
Settlement For the per
Date By Account of Quantity Share Type of Trade Broker
- ---------- ----------- ----------- -------- --------- ------------- ------
======================================================================================
<S> <C> <C> <C> <C> <C> <C>
07/25/97 Partners PAL 800 $11.5625 Purchase ABSB
- --------------------------------------------------------------------------------------
07/25/97 Partners ZPG 500 $11.5625 Purchase ABSB
- --------------------------------------------------------------------------------------
07/25/97 Partners BVF Ltd. 6,000 $11.5625 Purchase ABSB
- --------------------------------------------------------------------------------------
07/31/97 Partners BVF 18,500 $11.1250 Purchase ABSB
- --------------------------------------------------------------------------------------
07/31/97 Partners ILL10 5,000 $11.1250 Purchase MLCO
- --------------------------------------------------------------------------------------
07/31/97 Partners BVF Ltd. 21,500 $11.1250 Purchase MLCO
- --------------------------------------------------------------------------------------
07/31/97 Partners BVF 13,500 $11.1250 Purchase MLCO
- --------------------------------------------------------------------------------------
08/07/97 Partners BVF 10,000 $11.3750 Purchase COWN
- --------------------------------------------------------------------------------------
08/07/97 Partners ILL10 1,500 $11.3750 Purchase COWN
- --------------------------------------------------------------------------------------
08/07/97 Partners ZPG 1,000 $11.3750 Purchase COWN
- --------------------------------------------------------------------------------------
08/07/97 Partners BVF Ltd. 5,500 $11.3750 Purchase COWN
- --------------------------------------------------------------------------------------
</TABLE>
ABSB = Alex Brown
COWN = Cowen & Co.
MLCO = Merrill Lynch & Co.
